Tacrolimus: Approved and Unapproved Dermatologic Indications/Uses—Physician's Sequential Literature Survey: Part II

Authors

  • Virendra N. Sehgal MD,

    1. From the Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, Delhi;1the Skin Institute and School of Dermatology, Greater Kailash, New Delhi;2 and the Department of Dermatology, Venereology and Leprology, Institute of Medical Education and Research, Chandigarh, India3
    Search for more papers by this author
  • 1 Govind Srivastava MD,

    1. From the Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, Delhi;1the Skin Institute and School of Dermatology, Greater Kailash, New Delhi;2 and the Department of Dermatology, Venereology and Leprology, Institute of Medical Education and Research, Chandigarh, India3
    Search for more papers by this author
  • and 2 Sunil Dogra MD, DNB 3

    1. From the Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, Delhi;1the Skin Institute and School of Dermatology, Greater Kailash, New Delhi;2 and the Department of Dermatology, Venereology and Leprology, Institute of Medical Education and Research, Chandigarh, India3
    Search for more papers by this author

Virendra N. Sehgal, MD, FNASc, FAMS, FRAS (Lond), Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, A/6, Panchwati, Delhi-110 033, India
E-mail: drsehgal@ndf.vsnl.net.in

Abstract

Tacrolimus has been a useful therapeutic tool in dermatology practice ever since its inception. Accordingly, many “off-label” applications have been reported. Thus, its local immunosuppressive and steroid-sparing action stands recognized. Hence, its indications/uses were extended beyond atopic dermatitis to cover several dermatoses including other types of eczema, papulosquamous disorder of cornification, rosacea, other inflammatory skin conditions, vesicobullous disease, connective tissue disease, graft versus host disease, and follicular disorders. Many such diseases found to respond to tacrolimus therapy have been briefly recounted. It is worthwhile to conceive, however, that this topical immunomodulator should be reserved for use only as an alternative, should the conventional treatment be unresponsive. Hence, guarded use is warranted.

Ancillary